196 related articles for article (PubMed ID: 15474895)
21. The partial NMDA agonist D-cycloserine stimulates LH secretion in healthy volunteers.
van Berckel BN; Lipsch C; Gispen-de Wied C; Wynne HJ; Blankenstein MA; van Ree JM; Kahn RS
Psychopharmacology (Berl); 1998 Jul; 138(2):190-7. PubMed ID: 9718289
[TBL] [Abstract][Full Text] [Related]
22. D-cycloserine in Schizophrenia: New Strategies for Improving Clinical Outcomes by Enhancing Plasticity.
Goff DC
Curr Neuropharmacol; 2017; 15(1):21-34. PubMed ID: 26915421
[TBL] [Abstract][Full Text] [Related]
23. D-cycloserine added to clozapine for patients with schizophrenia.
Goff DC; Tsai G; Manoach DS; Flood J; Darby DG; Coyle JT
Am J Psychiatry; 1996 Dec; 153(12):1628-30. PubMed ID: 8942463
[TBL] [Abstract][Full Text] [Related]
24. d-Cycloserine augmentation of cognitive remediation in schizophrenia.
Cain CK; McCue M; Bello I; Creedon T; Tang DI; Laska E; Goff DC
Schizophr Res; 2014 Mar; 153(1-3):177-83. PubMed ID: 24485587
[TBL] [Abstract][Full Text] [Related]
25. Cognitive enhancers as adjuncts to psychotherapy: use of D-cycloserine in phobic individuals to facilitate extinction of fear.
Ressler KJ; Rothbaum BO; Tannenbaum L; Anderson P; Graap K; Zimand E; Hodges L; Davis M
Arch Gen Psychiatry; 2004 Nov; 61(11):1136-44. PubMed ID: 15520361
[TBL] [Abstract][Full Text] [Related]
26. Subunit-selective modulation of GABA type A receptor neurotransmission and cognition in schizophrenia.
Lewis DA; Cho RY; Carter CS; Eklund K; Forster S; Kelly MA; Montrose D
Am J Psychiatry; 2008 Dec; 165(12):1585-93. PubMed ID: 18923067
[TBL] [Abstract][Full Text] [Related]
27. Functional magnetic resonance imaging studies of schizophrenic patients during word production: effects of D-cycloserine.
Yurgelun-Todd DA; Coyle JT; Gruber SA; Renshaw PF; Silveri MM; Amico E; Cohen B; Goff DC
Psychiatry Res; 2005 Jan; 138(1):23-31. PubMed ID: 15708298
[TBL] [Abstract][Full Text] [Related]
28. Improvement of negative and positive symptoms in treatment-refractory schizophrenia: a double-blind, randomized, placebo-controlled trial with memantine as add-on therapy to clozapine.
de Lucena D; Fernandes BS; Berk M; Dodd S; Medeiros DW; Pedrini M; Kunz M; Gomes FA; Giglio LF; Lobato MI; Belmonte-de-Abreu PS; Gama CS
J Clin Psychiatry; 2009 Oct; 70(10):1416-23. PubMed ID: 19906345
[TBL] [Abstract][Full Text] [Related]
29. Placebo-controlled trial of glycine added to clozapine in schizophrenia.
Evins AE; Fitzgerald SM; Wine L; Rosselli R; Goff DC
Am J Psychiatry; 2000 May; 157(5):826-8. PubMed ID: 10784481
[TBL] [Abstract][Full Text] [Related]
30. Effect of bitopertin, a glycine reuptake inhibitor, on negative symptoms of schizophrenia: a randomized, double-blind, proof-of-concept study.
Umbricht D; Alberati D; Martin-Facklam M; Borroni E; Youssef EA; Ostland M; Wallace TL; Knoflach F; Dorflinger E; Wettstein JG; Bausch A; Garibaldi G; Santarelli L
JAMA Psychiatry; 2014 Jun; 71(6):637-46. PubMed ID: 24696094
[TBL] [Abstract][Full Text] [Related]
31. D-serine added to clozapine for the treatment of schizophrenia.
Tsai GE; Yang P; Chung LC; Tsai IC; Tsai CW; Coyle JT
Am J Psychiatry; 1999 Nov; 156(11):1822-5. PubMed ID: 10553752
[TBL] [Abstract][Full Text] [Related]
32. Efficacy of high-dose glycine in the treatment of enduring negative symptoms of schizophrenia.
Heresco-Levy U; Javitt DC; Ermilov M; Mordel C; Silipo G; Lichtenstein M
Arch Gen Psychiatry; 1999 Jan; 56(1):29-36. PubMed ID: 9892253
[TBL] [Abstract][Full Text] [Related]
33. D-cycloserine: an evolving role in learning and neuroplasticity in schizophrenia.
Goff DC
Schizophr Bull; 2012 Sep; 38(5):936-41. PubMed ID: 22368237
[TBL] [Abstract][Full Text] [Related]
34. Correlates of cognitive deficits in first episode schizophrenia.
Heydebrand G; Weiser M; Rabinowitz J; Hoff AL; DeLisi LE; Csernansky JG
Schizophr Res; 2004 May; 68(1):1-9. PubMed ID: 15037334
[TBL] [Abstract][Full Text] [Related]
35. D-Cycloserine added to risperidone in patients with primary negative symptoms of schizophrenia.
Evins AE; Amico E; Posever TA; Toker R; Goff DC
Schizophr Res; 2002 Jul; 56(1-2):19-23. PubMed ID: 12084415
[TBL] [Abstract][Full Text] [Related]
36. A trial of D-cycloserine to treat stereotypies in older adolescents and young adults with autism spectrum disorder.
Urbano M; Okwara L; Manser P; Hartmann K; Herndon A; Deutsch SI
Clin Neuropharmacol; 2014; 37(3):69-72. PubMed ID: 24824660
[TBL] [Abstract][Full Text] [Related]
37. d-cycloserine adjuvant therapy to conventional neuroleptic treatment in schizophrenia: an open-label study.
Cascella NG; Macciardi F; Cavallini C; Smeraldi E
J Neural Transm Gen Sect; 1994; 95(2):105-11. PubMed ID: 7865165
[TBL] [Abstract][Full Text] [Related]
38. Controlled trial of D-cycloserine adjuvant therapy for treatment-resistant major depressive disorder.
Heresco-Levy U; Javitt DC; Gelfin Y; Gorelik E; Bar M; Blanaru M; Kremer I
J Affect Disord; 2006 Jul; 93(1-3):239-43. PubMed ID: 16677714
[TBL] [Abstract][Full Text] [Related]
39. [Could we use a serum level of glycine as a prognostic factor of its efficacy in schizophrenic patients?].
Strzelecki D; Rabe-Jabłońska J
Psychiatr Pol; 2010; 44(3):395-404. PubMed ID: 20672518
[TBL] [Abstract][Full Text] [Related]
40. The Therapeutic Role of d-Cycloserine in Schizophrenia.
Goff D
Adv Pharmacol; 2016; 76():39-66. PubMed ID: 27288073
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
